3 results
Approved WMOCompleted
The primary efficacy objective of this study is to:* Compare the incidences of the composite endpoints of stroke, systemic embolic event (SEE), myocardial infarction (MI) and cardiovascular (CV) mortality between the edoxaban group and the…
Approved WMOCompleted
To study whether a novel plaster (Rapydan) is more successfull in diminishing pain/ discomfort than the usual plaster (EMLA).
Approved WMOCompleted
* To assess the effect of Edoxaban versus vitamin K antagonist (VKA) on net adverse clinical events (NACE), i.e., the composite of all-cause death, myocardial infarction (MI), ischemic stroke, systemic thromboembolism (SEE), valve thrombosis, and…